このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

A Study Evaluating the Antipyretic Efficacy and Safety of an Acetaminophen/Naproxen Sodium Fixed Combination in Subjects With Endotoxin-Induced Fever

2026年11月17日 更新者:Kenvue Brands LLC

A Randomized, Single-Dose, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Antipyretic Efficacy and Safety of an Acetaminophen/Naproxen Sodium Fixed Combination in Subjects With Endotoxin-Induced Fever

To evaluate the antipyretic efficacy of a single dose of a fixed combination of acetaminophen/naproxen sodium, compared with placebo.

調査の概要

詳細な説明

This will be a randomized, single-dose, double-blind, placebo-controlled, parallel-group study to evaluate the antipyretic efficacy and safety of a fixed-dose combination (FDC) of acetaminophen/naproxen sodium in adult subjects with endotoxin-induced fever, compared to placebo.

The study will be conducted in two study phases (Phase A and Phase B), with the intent of Phase A being for endotoxin dose evaluation and the intent of Phase B being to evaluate the investigational product (IP)/placebo.

Subjects enrolled in Phase A will not be included in Phase B, nor will data from these subjects be included in the statistical analysis. Phase A will be completed prior to starting Phase B. Data from Phase A will be reviewed by the Phase A Data Review Team to determine if a satisfactory endotoxin dosing regimen has been achieved. Once a satisfactory dosing regimen is determined, separate subjects will be enrolled in Phase B. Once the endotoxin induced qualifying fever (temperature ≥38.1°C) is established, eligible subjects will be randomized in a 1:1 allocation to receive a single dose of either the IP or the placebo

研究の種類

介入

入学 (推定)

292

段階

  • フェーズ 3

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究場所

    • Tennessee
      • Knoxville、Tennessee、アメリカ、37920
        • 募集
        • AMR Clinical - Knoxville Tennessee
        • コンタクト:

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年~55年 (大人)

健康ボランティアの受け入れ

はい

受講資格のある性別

男

説明

Inclusion Criteria

Subjects must meet all of the following inclusion criteria in Sections A and B to be eligible for enrollment into the study:

A) Assessed at Screening Visit (Visit 1):

  1. Has a body mass index (BMI) of 17.5 to 37.0 (inclusive) for subjects who are 18 to 40 years old or a BMI of 17.5 to 35.0 (inclusive) for subjects who are 41 to 55 years old.
  2. Healthy, defined as having no clinically relevant abnormalities or medical conditions identified by a detailed medical history; full physical examination; blood pressure, respiratory rate, and heart rate measurements; 12-lead ECG; and clinical laboratory tests conducted at Visit 1.
  3. Has abstained from all food and drink except water at least 4 hours prior to the clinical laboratory tests at Visit 1.
  4. Has a negative QuantiFERON-TB Gold Plus tuberculosis, hepatitis B surface antigen, hepatitis C antibody, and human immunodeficiency virus (HIV) test based on clinical laboratory tests at Visit 1.
  5. Has a negative urine drug screening test and a negative breath alcohol test conducted at Visit 1.
  6. Has adequate veins, as determined by visual inspection at Visit 1, for IV catheter insertion.
  7. Is able to comprehend the requirements of the study (based upon clinical site personnel's assessment) and is willing and able to comply with scheduled visits, procedures, and subject responsibilities specified within the informed consent form (ICF).
  8. Has provided written informed consent before participating in any study specific procedures.
  9. Agrees to follow contraception requirements (as defined in the protocol/ICF) for the duration of the study and for at least 30 days after study completion.
  10. Is a non-tobacco/nicotine user or previous user who completely stopped smoking/using any form of tobacco or nicotine-containing product at least 6 months before Visit 1.

B) Assessed at Day 0 and Day 1 (of Visit 2):

  1. Healthy, defined as having no clinically relevant abnormalities or medical conditions identified by a detailed medical history; full physical examination conducted on Day 0 (and symptoms-driven physical exam on Day 1, if applicable); blood pressure, respiratory rate, and heart rate measurements (conducted on Day 0 and Day 1); 12-lead ECG (conducted on Day 1), and clinical laboratory tests (conducted on Day 0).
  2. Has abstained from all food and drink except water at least 4 hours prior to the clinical laboratory tests on Day 0.
  3. Has a negative* urine drug screening test and a negative breath alcohol test conducted on Day 0 (*including a negative result for THC. A positive urine drug screening test for medications that have been prescribed to the subject are acceptable).
  4. Has adequate veins, as determined by visual inspection on Day 0, for IV catheter insertion.
  5. Has an oral temperature between 36.37 °C and 37.21 °C as measured on Day 0 and Day 1. If the subject's oral temperature is not between 36.37 °C and 37.21 °C after a single reading, then 2 additional oral temperature readings will be obtained within a 30-minute period. The average of these 3 consecutive temperature readings must be between 36.37 °C and 37.21 °C, with the highest value within 0.1 °C of the lowest temperature value.
  6. Agrees to follow contraception requirements (as defined in the protocol/ICF) for the duration of the study and for at least 30 days after study completion.

C) Assessed Once Qualifying Fever Established (Randomization Criteria; Phase B Only) Subjects must meet all of the following criteria following endotoxin administration in order to be randomized during Phase B. Subjects who do not meet these criteria will not be randomized.

  1. Has not experienced an allergic reaction or exaggerated systemic response to administration of endotoxin, as determined by the PI or medically qualified designee.
  2. Has not required medical management of an AE that includes an antipyretic treatment.
  3. Has developed an oral temperature of at least 38.1 ºC after endotoxin dosed per study guidelines.

Exclusion Criteria (to be assessed at Visit 1, Day 0 of Visit 2, and Day 1 of Visit 2).

Subjects must not meet any of the following exclusion criteria to be eligible for enrollment into the study

  1. Has a pregnant or nursing partner or a partner who is currently trying to become pregnant.
  2. Is self-reported to be unable to swallow whole large tablets or capsules.
  3. Has participated in any interventional clinical studies within 30 days before Visit 1.
  4. Is related to the persons involved directly or indirectly with the conduct of this study (PI, Sub-Investigator(s), study coordinators, other site personnel, employees/contractors of Kenvue or its subsidiaries, employees of IQVIA) at Visit 1.
  5. Has a known allergy or hypersensitivity to acetaminophen, naproxen, naproxen sodium, ibuprofen, other nonsteroidal anti-inflammatory drugs (NSAIDs) (including acetylsalicylic acid or other salicylates), any of the inactive ingredients in the products, ondansetron, or the endotoxin used in the study.
  6. Has a history of chronic tranquilizer use, heavy drinking, or substance abuse, as judged by the PI or designee, in the last five years.
  7. To be assessed at Day 0: Has consumed alcohol within 48 hours prior to Day 0.
  8. To be assessed at Day 0: Has consumed caffeine or other methylxanthine containing products (e.g., chocolate bars or chocolate beverages, coffee, tea, cola, or caffeinated energy drinks) within 24 hours prior to Day 0.
  9. To be assessed at Day 0: Has experienced cold/flu symptoms (i.e., runny nose, cough, pain, and/or fever) within 2 weeks prior to Day 0.
  10. To be assessed at Day 0: Has used prescription or nonprescription drugs within 5 half-lives prior to Day 0.
  11. To be assessed at Day 0: Has used any drug that may impact gastric motility, such as glucagon-like peptide-1 (GLP-1) medication, within 35 days prior to Day 0.
  12. To be assessed at Day 0: Has used vitamins or dietary/herbal supplements within 7 days prior to Day 0.
  13. Routinely uses oral analgesics ≥ 5 times per week.
  14. Has any disease or condition that may cause abnormal alterations in body temperature.
  15. Has a clotting/bleeding disorder and is at risk of excessive bleeding.
  16. Has evidence or history of a clinically significant laboratory abnormality or hematological, renal, endocrine, pulmonary, cardiovascular, hepatic, psychiatric, neurologic, immunologic, or allergic disease (excluding untreated, asymptomatic, seasonal allergies at the time of dosing) within the last 5 years that, in the PI's or medically qualified designee's opinion, may jeopardize the subject's safety or well-being or the integrity of the study.
  17. Has any clinically significant gastrointestinal disorder/disease/condition or is taking medication for any such disorder/disease/condition that, per the PI's or medically qualified designee's judgement, could affect the absorption, metabolism, or excretion of the study medication.
  18. Has a history of recurrent, acute, or chronic infections of any type or any findings suggestive of occult infection, such as tuberculosis, sinusitis, urinary tract infection, respiratory tract or dental (abscess) infection, etc. Also excluded are subjects with frequent (more than 3 outbreaks per year), recurrent oral or genital herpes, recurrent herpes zoster, or any infection otherwise judged by the PI or medically qualified designee to have the potential for exacerbation by participation in the study.
  19. Heart rate < 50 bpm or is deemed to be at high risk of syncope and/or hypotension per the clinical judgment of the PI or medically qualified designee at Visit 1, on Day 0, or on Day 1.
  20. Supine blood pressure <90 or >140 mmHg (systolic) or <50 or >90 mmHg (diastolic), following at least 5 minutes of supine rest, as assessed at Visit 1, on Day 0, or on Day 1.
  21. Supine 12-lead ECG demonstrating QTcF >450 msec or a QRS interval >120 msec at Visit 1 or on Day 1 prior to endotoxinadministration.
  22. Other severe, acute or chronic medical or psychiatric condition(s) or laboratory abnormality(ies) that may increase the risk associated with study participation or ISM administration or may interfere with the interpretation of study results.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:トリプル

武器と介入

参加者グループ / アーム
介入・治療
実験的:Acetaminophen 650 mg/Naproxen Sodium 220 mg

Acetaminophen 650 mg/Naproxen Sodium 220 mg (administered as two tablets of Acetaminophen/Naproxen Sodium 325 mg/110 mg).

The IP is to be taken as a single dose (administered as two tablets of Acetaminophen/Naproxen Sodium 325 mg/110 mg) orally with 180 mL of room temperature water.

プラセボコンパレーター:Placebo

Placebo (administered as two tablets of placebo).

The placebo is to be taken as a single dose (administered as two tablets of placebo) orally with 180 mL of room temperature water.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Time-weighted Sum of Temperature Differences (WSTD) from 0 to 8 hours (WSTD 0-8)
時間枠:Baseline (0 hour) up to 8 hours

WSTD 0-8 was defined as time-weighted sum of temperature differences over 8 hours, weighted by time elapsed between each 2 consecutive time points post treatment (5,10, 15,20,25,30,35,40,45,50, 55,60,70,80, 90,100, 110,120,150,180,210,240,270,300,330,360,390,420,450, and 480 minutes after the investigational study material (ISM) administration (Hour 0). Temperature difference was defined as baseline temperature (at Hour 0) minus the post-baseline temperature at each time point up to 8 hours (5,10, 15,20,25,30,35,40,45,50, 55,60,70,80, 90,100, 110 minutes,2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, and 8 hours).

Baseline (0 hour) up to 8 hours
Time-weighted Sum of Temperature Differences (WSTD) from 0 to 12 hours (WSTD 0-12)
時間枠:Baseline (0 hour) up to 12 hours

WSTD 0-12 was defined as time-weighted sum of temperature differences over 8 hours, weighted by time elapsed between each 2 consecutive time points post treatment (5,10, 15,20,25,30,35,40,45,50, 55,60,70,80,90,100,110,120,150,180,210,240,270,300,330,360,390,420,450, 480,510,540,570,600,630,660,690,and 720 minutes after the investigational study material (ISM) administration (Hour 0). Temperature difference was defined as baseline temperature (at Hour 0) minus the post-baseline temperature at each time point up to 12 hours (5,10, 15,20,25,30,35,40,45,50, 55,60,70,80, 90,100, 110 minutes,2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 10.5, 11, 11.5 , and 12 hours).

Baseline (0 hour) up to 12 hours

二次結果の測定

結果測定
メジャーの説明
時間枠
Time-weighted Sum of Temperature Differences (WSTD) from 0 to 6 hours (WSTD 0-6)
時間枠:Baseline (0 hour) up to 6 hours

WSTD 0-6 was defined as time-weighted sum of temperature differences over 8 hours, weighted by time elapsed between each 2 consecutive time points post treatment (5,10, 15,20,25,30,35,40,45,50, 55,60,70,80, 90,100, 110,120,150,180,210,240,270,300,330, and 360 minutes after the investigational study material (ISM) administration (Hour 0). Temperature difference was defined as baseline temperature (at Hour 0) minus the post-baseline temperature at each time point up to 6 hours (5,10, 15,20,25,30,35,40,45,50, 55,60,70,80, 90,100, 110 minutes,2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, and 6 hours).

Baseline (0 hour) up to 6 hours
Time-weighted Sum of Temperature Differences (WSTD) from 0 to 10 hours (WSTD 0-10)
時間枠:Baseline (0 hour) up to 10 hours

WSTD 0-10 was defined as time-weighted sum of temperature differences over 8 hours, weighted by time elapsed between each 2 consecutive time points post treatment (5,10, 15,20,25,30,35,40,45,50, 55,60,70,80,90,100,110,120,150,180,210,240,270,300,330,360,390,420,450, 480,510,540,570, and 600 minutes after the investigational study material (ISM) administration (Hour 0). Temperature difference was defined as baseline temperature (at Hour 0) minus the post-baseline temperature at each time point up to 10 hours (5,10, 15,20,25,30,35,40,45,50, 55,60,70,80, 90,100, 110 minutes,2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, and 10 hours).

Baseline (0 hour) up to 10 hours
Subject Global Evaluation Questionnaire
時間枠:Visit 2 - 12 hours prior to first use of rescue medication, or at time of early discontinuation (whichever occurs first).

Participants will be asked to evaluate the performance of the investigational study material (ISM) using a 5-point Likert scale : 0= poor , 1=fair , 2=good , 3=very good , 4=excellent

Visit 2 - 12 hours prior to first use of rescue medication, or at time of early discontinuation (whichever occurs first).
Time to first use of rescue medication
時間枠:Baseline (0 hour) to 12 hours

Time to rescue medication (other than study treatment) was defined as time from first dosing of study medication to the time a participant first takes a rescue medication, or to the end of the study time for participants that do not take any rescue medication prior to the end of the study. The rescue medication was defined as medication received for the treatment of fever during the time period from the administration of study medication to the time of end of the study.

Baseline (0 hour) to 12 hours
Proportion of subjects using rescue medication from 0 to 12 hours
時間枠:Baseline (0 hour) to 12 hours
Baseline (0 hour) to 12 hours

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • スタディディレクター:Tobore Tobore、Kenvue Brands LLC

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2026年10月20日

一次修了 (推定)

2027年10月29日

研究の完了 (推定)

2027年10月29日

試験登録日

最初に提出

2026年10月15日

QC基準を満たした最初の提出物

2026年11月17日

最初の投稿 (実際)

2026年11月19日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月19日

QC基準を満たした最後の更新が送信されました

2026年11月17日

最終確認日

2026年11月11日

詳しくは

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する